Verve Therapeutics, Inc. (VERV), a clinical-stage company pioneering gene editing medicines for cardiovascular disease, will participate in two upcoming investor conferences in June:
Jefferies Global Healthcare Conference - June 4, 2025, at 9:20 a.m. ET, New York, NY
Goldman Sachs 46th Annual Global Healthcare Conference - June 9, 2025, at 11:20 a.m. ET, Miami, FL
Pipeline Updates:
VERVE-102 is an investigational, in vivo base editing therapy designed to permanently turn off the PCSK9 gene in the liver, offering a potential one-time treatment for heterozygous familial hypercholesterolemia or HeFH and patients with premature coronary artery disease.
Initial data from the Heart-2 Phase 1b trial showed a mean LDL-C reduction of 53 percent, with a maximum drop of 69 percent at the 0.6 mg/kg dose level after a single infusion.
No treatment-related serious adverse events were reported.
The company expects to begin Phase 2 dosing in the second half of 2025, subject to regulatory clearance.
Verve also received FDA Fast Track designation for VERVE-102 in March and is on track to deliver an opt-in data package to Eli Lilly, with a partnership decision expected in the second half of 2025.
VERVE-201, targeting the ANGPTL3 gene for patients with refractory hypercholesterolemia and HoFH, continues in the Pulse-1 Phase 1b trial, with a program update anticipated later this year.
VERVE-301, targeting Lp(a), is in preclinical development under Verve's collaboration with Lilly. The company received a milestone payment from Lilly in Q1 2025 following the nomination of VERVE-301 as the development candidate.
Q1 Performance:
Verve reported a net loss of $31.0 million, or $0.35 per share, in the first quarter of 2025, compared to $48.7 million, or $0.59 per share, in Q1 2024.
R&D expenses totaled $54.5 million, up from $48.4 million in the same quarter last year, with stock-based compensation of $5.6 million.
General and administrative expenses were $15.2 million, compared to $14.2 million in Q1 2024, including $5.6 million in stock-based compensation.
Cash Position:
Verve ended the quarter with $497.1 million in cash, cash equivalents, and marketable securities, providing a cash runway into mid-2027.
Currently, VERV is trading at $4.8, up by 7.8 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.